Dynamic bias and its implications for GPCR drug discovery

This publication has 17 references indexed in Scilit:

• Signalling bias in new drug discovery: detection, quantification and therapeutic impact
  Nature Reviews Drug Discovery, 2012
• Impedance Responses Reveal β2-Adrenergic Receptor Signaling Pluridimensionality and Allow Classification of Ligands with Distinct Signaling Profiles
  PLOS ONE, 2012
• EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
  European Urology, 2011
• Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
  Nature Reviews Drug Discovery, 2010
• A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling
  Proceedings of the National Academy of Sciences, 2007
• β-adrenoceptor blocker treatment and the cardiac β-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure
  Naunyn-Schmiedeberg's Archives of Pharmacology, 2007
• Distinct Signaling Profiles of β1 and β2 Adrenergic Receptor Ligands toward Adenylyl Cyclase and Mitogen-Activated Protein Kinase Reveals the Pluridimensionality of Efficacy
  Molecular Pharmacology, 2006
• The Salmeterol Multicenter Asthma Research Trial
  Chest, 2006
• Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
  The Lancet, 2003
• Characterization of β₁‐selectivity, adrenoceptor‐G_s‐protein interaction and inverse agonism of nebivolol in human myocardium
  British Journal of Pharmacology, 2001